In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback